NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease

International Journal of Developmental Neuroscience

Volumn 16, Issue 7-8, 1998, Pages 787-794

  Hellweg, Rainer ^b   Gericke, Christian A ^d   Jendroska, Klaus ^a   Hartung, Heinz Dieter ^b   Cervós Navarro, Jorge ^b,c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^d Univ Internacional de Catalunya ^*

Author keywords

A4; Alzheimer's disease; Amyloid; Cerebral cortex; ChAT; ELISA; Histoblot technique; NGF; Senile plaque

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINE ACETYLTRANSFERASE; MESSENGER RNA; NERVE GROWTH FACTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; CHOLINERGIC NERVE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; SENILE PLAQUE; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; DEMENTIA; FEMALE; FRONTAL LOBE; HUMANS; MALE; NERVE GROWTH FACTORS; TEMPORAL LOBE;

EID: 0032460880     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-5748(98)00088-4     Document Type: Article

References (41)

1. Allen, S. J., MacGowan, S. H., Treanor, J. J. S., Feeney, R., Wilcock, G. K. and Dawbarn, D., Normal β-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci. Lett., 1991, 131, 135-139.
2. Arendt, T., Taubert, G., Bigl, V. and Arendt, A., Amyloid deposition in the nucleus basalis of Meynert complex: a topographic marker for degenerating cell clusters in Alzheimer's disease. Acta Neuropathol., 1988, 75, 226-232.
3. Auld, D. S., Kar, S. and Quirion, R., β-Amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci., 1998, 21, 43-49.
4. Bierer, L. M., Haroutunian, V., Gabriel, S., Knott, P. J., Carlin, L. S., Purohit, D. P., Perl, D. P., Schmeidler, J., Kanof, P. and Davis, K. L., Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J. Neurochem., 1995, 64, 749-760.
5. Boissière F., Faucheux, B., Ruberg, M., Agid, Y. and Hirsch, E.C., Decreased trkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease. Exp. Neurol., 1997, 145, 245-252.
6. Boissière, F., Faucheux, B., Agid, Y. and Hirsch, E. C., Expression of catalytic trkB gene in the striatum and the basal forebrain of patients with Alzheimer's disease: an in situ hybridization study. Neurosci. Lett., 1997, 221, 141-144.
7. Boissière, F., Hunot, S., Faucheux, B., Duyckaerts, C., Hauw, J. J., Agid, Y. and Hirsch E. C., Nuclear translocation of NF-κB in cholinergic neurons of patients with Alzheimer's disease. NeuroReport, 1997, 8, 2849-2852.
8. Crutcher, K. A., Scott, S. A., Liang, S., Everson, W. V. and Weingartner, J., Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J. Neurosci., 1993, 13, 2540-2550.
9. Ernfors, P., Lindefors, N., Chan-Palay, V. and Persson, H., Cholinergic neurons of the nucleus basalis express elevated levels of nerve growth factor receptor mRNA in senile dementia of the Alzheimer type. Dementia, 1990, 1, 138-145.
10. Fahnestock, M., Scott, S. A., Jetté, N., Weingartner, J. A. and Crutcher K. A., Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Mol. Brain Res., 1996, 42, 175-178.
11. Fonnum, F., A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem, 1975, 24, 407-409.
12. Goedert, M., Fine, A., Hunt, S. P. and Ullrich, A., Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. Mol. Brain Res., 1986, 1, 85-92.
13. Hardy, J., Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci., 1997. 20, 154-159.
14. Hellweg, R., Hock, C. and Hartung, H. D., An improved rapid and highly sensitive enzyme immunoassay for nerve growth factor. Technique-J. Methods Cell. Mol. Biol., 1989, 1, 43-49.
15. Hellweg, R., Baethge, C., Hartung, H.-D., Brückner, M. K. and Arendt, T., NGF level in the rat sciatic nerve is decreased after long-term consumption of ethanol. NeuroReport, 1996, 7, 777-780.
16. Hellweg, R., von Richtofen, S., Anders, D., Baethge, C., Röpke, S., Hartung, H.-D. and Gericke, C. A., The time course of nerve growth factor content in different neuropsychiatrie diseases - a unifying hypothesis. J. Neural Transm., 1998, 105, 871-903.
17. Hock, C., Heese, K., Müller-Spahn, F., Hulette, C., Rosenberg, C. and Otten U., Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neurosci. Lett., 1998, 241, 1-4.
18. Hörtnagel, H. and Hellweg, R., Insights into the role of the cholinergic component of the septohippocampal pathway: what have we learned from experimental lesion studies? Brain Res. Bull., 1997, 43, 245-255.
19. Hörtnagel, H. and Hellweg, R., Pathophysiological aspects of human neurodegenerative diseases. Wien. Klin. Wochenschr., 1997, 109(16), 623-635.
20. trk mRNA marks NGF-responsive forebrain neurons: evidence that trk gene expression is induced by NGF. Neuron, 1992, 9, 465-478.
21. Itoh, A., Nitta, A., Nadai, M., Nishimura, K., Hirose, M., Hasegawa, T. and Nabeshima, T., Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rats. J. Neurochem., 1996, 66, 1113-1117.
22. Jendroska, K., Poewe, W., Daniel, S. E., Pluess, J., Iwerssen-Schmidt, H., Paulsen, J., Barthel, S., Schelosky, L., Cervós-Navarro, J. and DeArmond, S. J., Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol., 1995, 90, 461-466.
23. Jetté, N., Cole, M. S. and Fahnestock, M., NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Mol. Brain Res., 1994, 25, 242-250.
24. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K. and Müller-Hill, B., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature, 1987, 325, 733-736.
25. Kaplan, D. R. and Miller, F. D., Signal transduction by the neurotrophin receptors. Curr. Opin. Cell. Biol., 1997, 9, 213-221.
26. Masters, C. L. and Bayreuther, K., Amyloid: cause or effect in Alzheimer's disease. In Neurodegenerative Disorders: Mechanisms and Prospects for Therapy, ed. D. L. Price, H. Thoenen and A. J. Aguayo. John Wiley and Sons, West Sussex, 1991, pp. 75-86.
27. Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Van Belle, G. and Berg, L., The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) - part II: standardization of the neuropathological assessment of Alzheimer's disease. Neurology, 1991, 41, 479-486.
28. Mufson, E. J. and Kordower, J. H., Cortical neurons express nerve growth factor receptors in advanced age and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 569-573.
29. Mufson, E. J., Conner, J. M. and Kordower, J. H., Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. NeuroReport, 1995, 6, 1063-1066.
30. Mufson, E. J., Li, J. M., Sobreviela, T. and Kordower, J. H., Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. NeuroReport, 1996, 8, 25-29.
31. Mufson, E. J., Lavine, N., Jaffar, S., Kordower, J. H., Quirion, R. and Saragovi, H. U., Reduction in p140-trkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp. Neurol., 1997, 146, 91-103.
32. Narisawa-Saito, M., Wakabayashi, K., Tsuji, S., Takahashi, H. and Nawa H., Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. NeuroReport, 1996, 7, 2925-2928.
33. Phillips, H. S., Hains, J. M., Armanini, M., Laramee, G. R., Johnson, S. A. and Winslow J. W., BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron, 1991, 7, 695-702.
34. Salehi, A., Verhaagen, J., Dijkhuizen, P. A. and Swaab, D. F., Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience, 1996, 75, 373-387.
35. Scott, S. A. and Crutcher, S. A., Nerve growth factor and Alzheimer's disease. Rev. Neurosci., 1994, 5, 179-211.
36. Scott, S. A., Mufson, E. J., Weingartner, J. A., Skau, K. A. and Crutcher, K. A., Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J. Neurosci., 1995, 15, 6213-6221.
37. Selkoe, D. J., Alzheimer's disease: a central role for amyloid. J. Neuropath. Exp. Neurol., 1994, 53, 438-447.
38. White, H. L. and Cavallito, C. J., Inhibition of bacterial and mammalian choline acetyltransferases by styrylpyridine analogues. J. Neurochem., 1970, 17, 1579-1589.
39. Wisniewski, Th., Ghiso, J. and Frangione, B., Biology of Aβ amyloid in Alzheimer's disease. Neurobiol. Disease, 1997, 4, 313-328.
40. Woolf, N. J., Gould, E. and Butcher, L. L., Nerve growth factor receptor is associated with cholinergic neurons of the basal forebrain but not the pontomesencephalon. Neuroscience, 1989, 30, 143-152.
41. Woolf, N. J., Jacobs, R. W. and Butcher, L. L., The pontomesencephalotegmental cholinergic system does not degenerate in Alzheimer's disease. Neurosci. Lett., 1989, 96, 277-282.